Development of therapeutic antibodies for the treatment of diseases

I am pleased to publish the first-author review paper in the Journal of Biomedical Science in Jan 2020. In this review, we introduce the latest antibody drug market and fully list 79 US FDA-approved antibodies in the current. The global therapeutic monoclonal antibody market was valued at approximately US$115.2 billion in 2018 and is expected to generate revenue of $150 billion by the end of 2019 and $300 billion by 2025. The market for therapeutic antibody drugs has experienced explosive growth as new drugs have been approved for treating various human diseases, including many cancers, autoimmune, metabolic and infectious diseases.

We describe in detail the preeminent antibody engineering technologies used in the development of therapeutic antibody drugs, such as humanization of monoclonal antibodies, phage display, the human antibody mouse, single B cell antibody technology, and affinity maturation.

Until now, there are quite rare papers in the literature to completely depict the human antibody transgenic mice. Here, we outline the major companies of Ab transgenic mice in the world. We also introduce the methodology of XenoMouse establishment.

Finally, we hope you will enjoy reading this paper.